Quantity of qualified people: CDEC discussed the uncertainty in the quantity of clients with moderately significant to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some sufferers who are categorized as possessing mild or moderate disorder could possibly have a serious